IMPLEMENTATION ROLLING PLAN Regulation (EU) 2017/745 and Regulation (EU) 2017/746

This rolling plan contains a list of identified essential implementing acts and other relevant initiatives that the Commission has adopted or intends to adopt in the future. This plan is divided into two sections: implementing acts, and other actions/initiatives. This document is subject to quarterly review in order to provide national authorities and stakeholders with the most updated information.

This document shall be read in conjunction with the "MDR/IVDR roadmap" adopted by the Competent Authorities for Medical Devices (CAMD) in cooperation with the Commission (available at https://www.camdeurope.eu/regulatory/medical-devices-regulation-vitro-diagnostics-regulation-mdr-ivdr-roadmap). A list of ongoing MDCG guidance documents is available at https://ec.europa.eu/docsroom/documents/37921.

NOTE: Regulation (EU) 2020/561 of the European Parliament and of the Council deferred by one year the date of application of Regulation (EU) 2017/745, until 26 May 2021. Regulation (EU) 2022/112 of the European Parliament and of the Council extended the transitional provisions of Regulation (EU) 2017/746.

No.	. Subject	Legal basis	Description IMPLEMENTING ACTS	Expected timelines (expected date of final adoption/date of accomplishment)	
1	Notified bodies scope of designation	Article 42(13) MDR Article 38(13) IVDR	Commission Implementing Regulation (EU) 2017/2185 Definition of the list of codes and corresponding types of devices for the purpose of specifying the scope of the designation of notified bodies. This action is an essential pre- condition for the launch of the designation procedure for notified bodies.	24 November 2017	
2	Reprocessing of single-use devices	Article 17(5) MDR	Commission Implementing Regulation (EU) 2020/1207 Common specifications laying down requirements related to reprocessing of single-use devices concerning risk management, including the analysis of the construction and material, related properties of the device (reverse engineering) and procedures to detect changes in the design of the original device as well as of its planned application after reprocessing; the validation of procedures for the entire process, including cleaning steps; the product release and performance testing; the quality management system; the reporting of incidents involving devices that have been reprocessed; and the traceability of reprocessed devices.	Q3 2020	

Latest update: July 2022

State-of-play/Next step

Published on 24 November 2017. COMPLETED

Published on 20 August 2020. COMPLETED

No.	Subject	Legal basis	Description	Expected timelines (expected date of final adoption/date of accomplishment)	
			Commission implementing act		
3	for products without a	Articles 1(2) and 9(1) MDR	Common specifications (CS) addressing for any of the groups of products listed in Annex XVI of the MDR, at least, application of risk management as set out in Annex I and, where necessary, clinical evaluation regarding safety. Application of MDR to Annex XVI products depends on the adoption of CS.	Updated information to be provided following the next meeting of the Committee on Medical Devices	Discussion Devices. N of the Comito comr
			Commission implementing act	Updated information to be	
3a	Reclassification of certain Annex XVI active products	Article 51(3)	on reclassification of groups of active products without an intended medical purpose, by way of derogation from Annex VIII to Regulation (EU) 2017/745 of the European Parliament and of the Council.	provided following the submission of a formal request from one or more Member States	
			Commission Implementing Decision (EU) 2019/1396		
4	Setting up of expert panels	recital 94 Article 106(1) MDR	Making provision for expert panels to be designated. Based on this implementing act, the selection of experts will be carried out. Expert panels are tasked inter alia with the delivery of opinions on the clinical evaluation of certain high-risk devices in the context of the pre-market scrutiny. Tasks of expert panels are described in Article 106(10).		
5		recital 94 Articles 48(6), 100(1) and (3) IVDR, Article 113(d) IVDR	Implementing Act (no comitology involved) Designation of EU reference laboratories, active in the IVD field. Tasks are described in Article 100. Designation may take place no earlier than 25 November 2020, according to IVDR Article 113(d).	Q1 2023	
6	Rules to facilitate fulfilment of tasks by EU reference laboratories and to ensure their compliance with criteria	Article 100(8)(a)	Implementing Act Rules to facilitate application of IVDR Article 100 (2) listing the tasks of the EURLs; rules to ensure compliance with criteria for an EURL listed in IVDR Article 100 (4). Date of application of the act may not be earlier than 25 November 2020 according to IVDR Article 113(d).	Q2 2022	
7	Fees for EURL services	Article 100(8)(b) IVDR	Implementing Act Definition of rules for fees for the advice/testing activities performed by EURL. Date of application of the act may not be earlier than 25 November 2020 according to IVDR Article 113(d).	Q2 2022	
	Unique Device Identification (UDI)	Article 27(2) MDR	Commission Implementing Decision (EU) 2019/939		
8	System: designation of	Article 24(2) IVDR	Designation of one or more entities to operate a system for assignment of UDIs ('issuing entity').	6 June 2019	

State-of-play/Next step

In progress.

ssions ongoing within the Committee on Medical . Minutes of the meetings, voting sheets and drafts he voted measures are available online on the hitology register website. A new meeting of the mmittee will be convened in September 2022

In preparation

Published on 10 September 2019. COMPLETED

In preparation

Published on 17 June 2022. COMPLETED

Published on 17 June 2022. COMPLETED

Published on 6 June 2019. COMPLETED

No.	Subject	Legal basis	Description	Expected timelines (expected date of final adoption/date of accomplishment)			
9	Eudamed	Article 33(8) MDR Article 30(1) IVDR	Commission Implementing Regulation (EU) 2021/2226 of 14 December 2021 laying down rules for the application of Regulation (EU) 2017/745 of the European Parliament and of the Council as regards electronic instructions for use of medical devices. Definition of detailed arrangements necessary for the setting up and maintenance of Eudamed. This IA is mainly related to support, change management and maintenance rules.	14 December 2021			
10	Common specifications for IVD Class D	Article 9 and 48(6) IVDR	Commission implementing act Common Specifications for certain IVDs in class D. Important to facilitate conformity assessment by manufacturers, notified bodies, expert panels and EU reference laboratories.	Q2 2022			
11	MDR/IVDR standardisation request	Article 10 of Regulation (EU) No 1025/2012 (the 'Standardisation Regulation')	Commission Implementing Decision C(2021) 2406 (M/575) MDR/IVDR standardisation request to the relevant European standardisation organisations (CEN and CENELEC) for harmonised European standards in the field of medical devices in support of the new Regulations. Existing harmonised standards need to be revised, and new standards need to be developed.	Q2 2021 Q4 2022	Adopted or First amend		
12	Harmonised standards in support of MDR and IVDR	Articles 8(1) of the MDR and IVDR and correlatives	Commission Implementing Decisions Periodical publication in the OJEU of lists of references of harmonised standards to confer presumption of conformity with the requirements of the new Regulations the standards aim to cover.	Q2 2021, Q4 2021 Q2 2022, Q4 2022	First lists for New public and IVDR, aı New		
13	Unique Device Identification (UDI) System	Article 27 (10) (b)	Commission Delegated Regulation on UDI assignment criteria for highly individualised devices (contact lenses)	Q1 2023			
	ACTIONS/INITIATIVES (OTHER THAN IMPLEMENTING REGULATIONS/ACTS)						
1	Notified bodies designation		Designation of notified bodies under the MDR and IVDR. Designation of notified bodies under the Regulations is a pre-condition for carrying out conformity assessments under those Regulations. List of notified bodies under MDR/IVDR available at: https://ec.europa.eu/growth/tools- databases/nando/index.cfm?fuseaction=directive.main	Notified bodies are designated on a roling basis	See t Org		
3	Eudamed: drawing up of functional specifications	Article 34(1) MDR	Functional specifications for Eudamed, to be drawn up by the Commission, in cooperation with the MDCG.	Q1 2019 (high-level functional specifications)	High-level		

State-of-play/Next step

Published on 14 December 2021 COMPLETED

Published on 4 July 2022. COMPLETED

on 14 April 2021, accepted by CEN and CENELEC on 12 May 2021. COMPLETED Indment to add and remove items in Annexes I and II, under development.

for MDR and IVDR, published in the OJEU on 19 and 20 July 2021 respectively. COMPLETED plications amending and enlarging the lists for MDR R, published in the OJEU on 5 and 7 January 2022,

and on 17 and 12 May 2022 respectively. COMPLETED w publications for further amendments and enlargements, in preparation.

In progress

e the New Approach Notified and Designated rganisations (NANDO) Information System.

el functional specifications publically issued on the Commission website in March 2019.

No.	Subject	Legal basis	Description	Expected timelines (expected date of final adoption/date of accomplishment)	
4	Eudamed: Audit of functional specifications and publication of the notice of full functionality	Article 34(2) and 34(3) MDR	Independent audit report based on which the Commission shall inform the MDCG that Eudamed has achieved full functionality and meets the drawn up functional specifications. Publication of the notice of achieved full functionality.	Q1/Q2 2024	Developmer ongoing perfo
6	Communication campaign		In order to avoid bottle necks and to ensure access to medical devices, a communication campaign targeting all stakeholders impacted by the Regulations is foreseen and supported by EU Health Programme. Targeted factsheets are produced for each target and the webpages of DG SANTE on medical devices will be updated to provide more accurate and updated information.	Updated information to be provided during the transitional period of the Regulations. Examples of deliverables are information factsheets, targeted presentations, dedicated website	The website live and i campaign Notification new
7	Expert advisory structure: Setting of MDCG	Article 103 MDR	Establishing the Medical Devices Coordination Group (MDCG). The Group is composed of designated experts from Member States and chaired by the Commission. The Group provides advice and guidance on all matters related to the implementation of the Regulations.	26 November 2017 (Legal deadline)	
8	Expert advisory structure: Setting of MDCG subgroups	Article 103 MDR	Setting of MDCG sub-groups, providing MDCG with the necessary expertise in relation to specific fields.	Establishment of MDCG Subgroup started in March 2019	Multiple Regulations (c
9	Mandate to SCHEER on phthalates	Annex I Section 10.4.3 MDR	Mandate to the scientific Committee (SCHEER) to prepare guidelines on phthalates. Available at: https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer _o_015.pdf	18 June 2019	
10	EU medical device nomenclature	Article 26 MDR and 23 IVDR	Designation of the future EU medical device nomenclature to be used in the UDI database	March 2019	Decision p
11	Report on delegated acts MDR/IVDR	Article 115 MDR, Article 108 IVDR	REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL on the exercise of the power to adopt delegated acts conferred on the Commission pursuant to Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices	26 April 2022	Adc

State-of-play/Next step

nent of the Minimum Viable Product (MVP) scope is ng and must be finalised before the audit can be formed. Audit of MVP planned for Q2 2024.

ite dedicated to the Medical Devices Regulations is d it is continuously being updated. Social media gn and targeted press release currently ongoing. ons are sent to subscribers of the Newsletter when w documents are published on the website.

Established by the legal deadline. COMPLETED

ple MDCG Subgroups for different areas of the ons operational since March 2019. Latest Subgroup (on Eudamed) established in April 2020. COMPLETED

> Adopted on 18 June 2019. COMPLETED

published on the Commission website in March 2019. COMPLETED

dopted on 26.4.2022, COM(2022)182 final. COMPLETED